Allogene Therapeutics, Inc. Common Stock
Here’s whether Allogene Therapeutics, Inc. Common Stock (ALLO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 65 — healthy momentum range; strong 1-year return of +91.6%. Concerns: 50-day MA is falling (-0.87% over 10 days); declining volume on rally — weak conviction (0.74x 30d avg). Currently 54.0% off its 52-week high. Score: +3/7.
ALLO is in a confirmed uptrend, trading above both its 50-day ($1.95) and 200-day ($1.90) moving averages. An RSI of 64.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +91.6% compares to +20.4% for SPY (beat the market by 71.2%). The current 54.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.